PreDiabetes Pipeline 2024: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis by DelveInsight | NanoPrecision Medical, Caelus Health, Inversago Pharma Inc., Haisco Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, PreDiabetes pipeline constitutes 15+ key companies continuously working towards developing 15+ PreDiabetes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"PreDiabetes Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/prediabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PreDiabetes Market.

The PreDiabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the PreDiabetes Pipeline Report:

*
Companies across the globe are diligently working toward developing novel PreDiabetes treatment therapies with a considerable amount of success over the years.

*
PreDiabetes companies working in the treatment market are NanoPrecision Medical, Caelus Health, Inversago Pharma Inc., Haisco Pharmaceutical Group Co., Ltd., Valbiotis, Resverlogix, Boston Therapeutics, and others, are developing therapies for the PreDiabetes treatment

*
Emerging PreDiabetes therapies in the different phases of clinical trials are- OKV-119, Anaerostipes rhamnosivorans, Intestinimonas, INV-202, HSK7653, Eubacterium Hallii, Totum-63, Apabetalone, BTI-320, and others are expected to have a significant impact on the PreDiabetes market in the coming years.

*
In November 2024, Eli Lilly and Company (NYSE: LLY) released detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), which is the longest completed study of tirzepatide to date. Weekly injections of tirzepatide (Zepbound Registered and Mounjaro Registered ) at combined doses of 5 mg, 10 mg, and 15 mg significantly reduced the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight, compared to a placebo, over the 176-week period. Tirzepatide also showed sustained average weight loss of 22.9% (with the 15 mg dose) throughout the three-year treatment period for the efficacy group.

PreDiabetes Overview

Pre-diabetes is a condition characterized by blood glucose levels that are higher than normal but not yet high enough to be diagnosed as type 2 diabetes. It's considered an intermediate stage between normal glucose levels and diabetes. Individuals with pre-diabetes are at increased risk of developing type 2 diabetes, heart disease, and stroke. However, pre-diabetes can often be reversed through lifestyle changes such as weight loss, healthy eating, and increased physical activity. Regular monitoring and early intervention can help prevent or delay the onset of type 2 diabetes in individuals with pre-diabetes.

Get a Free Sample PDF Report to know more about PreDiabetes Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/prediabetes-pipeline-insight [https://www.delveinsight.com/report-store/prediabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging PreDiabetes Drugs Under Different Phases of Clinical Development Include:

*
OKV-119: NanoPrecision Medical

*
Anaerostipes rhamnosivorans: Caelus Health

*
Intestinimonas: Caelus Health

*
INV-202: Inversago Pharma Inc.

*
HSK7653: Haisco Pharmaceutical Group Co., Ltd.

*
Eubacterium Hallii: Caelus Health

*
Totum-63: Valbiotis

PreDiabetes Route of Administration

PreDiabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Intravenous

*
Subcutaneous

PreDiabetes Molecule Type

PreDiabetes Products have been categorized under various Molecule types, such as

*
Small molecule

*
Cell Therapy

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

PreDiabetes Pipeline Therapeutics Assessment

*
PreDiabetes Assessment by Product Type

*
PreDiabetes By Stage and Product Type

*
PreDiabetes Assessment by Route of Administration

*
PreDiabetes By Stage and Route of Administration

*
PreDiabetes Assessment by Molecule Type

*
PreDiabetes by Stage and Molecule Type

DelveInsight's PreDiabetes Report covers around 15+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further PreDiabetes product details are provided in the report. Download the PreDiabetes pipeline report to learn more about the emerging PreDiabetes therapies [https://www.delveinsight.com/sample-request/prediabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the PreDiabetes Therapeutics Market include:

Key companies developing therapies for PreDiabetes are - Resverlogix Corporation, Boston Therapeutics, vTv Therapeutics, Valbiotis, BioTeSys, SynDevRx, Caelus Health, NanoPrecision Medical, and others.

PreDiabetes Pipeline Analysis:

The PreDiabetes pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of PreDiabetes with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PreDiabetes Treatment.

*
PreDiabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
PreDiabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PreDiabetes market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about PreDiabetes drugs and therapies [https://www.delveinsight.com/sample-request/prediabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

PreDiabetes Pipeline Market Drivers

*
Increase in prevalence of prediabetes, increase in Diagnosis and Growing investments in research and development are some of the important factors that are fueling the PreDiabetes Market.

PreDiabetes Pipeline Market Barriers

*
However, side effects associated with Drugs, lack of Awareness among Patients and other factors are creating obstacles in the PreDiabetes Market growth.

Scope of PreDiabetes Pipeline Drug Insight

*
Coverage: Global

*
Key PreDiabetes Companies: NanoPrecision Medical, Caelus Health, Inversago Pharma Inc., Haisco Pharmaceutical Group Co., Ltd., Valbiotis, Resverlogix, Boston Therapeutics, and others

*
Key PreDiabetes Therapies: OKV-119, Anaerostipes rhamnosivorans, Intestinimonas, INV-202, HSK7653, Eubacterium Hallii, Totum-63, Apabetalone, BTI-320, and others

*
PreDiabetes Therapeutic Assessment: PreDiabetes current marketed and PreDiabetes emerging therapies

*
PreDiabetes Market Dynamics: PreDiabetes market drivers and PreDiabetes market barriers

Request for Sample PDF Report for PreDiabetes Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/prediabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. PreDiabetes Report Introduction

2. PreDiabetes Executive Summary

3. PreDiabetes Overview

4. PreDiabetes- Analytical Perspective In-depth Commercial Assessment

5. PreDiabetes Pipeline Therapeutics

6. PreDiabetes Late Stage Products (Phase II/III)

7. PreDiabetes Mid Stage Products (Phase II)

8. PreDiabetes Early Stage Products (Phase I)

9. PreDiabetes Preclinical Stage Products

10. PreDiabetes Therapeutics Assessment

11. PreDiabetes Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. PreDiabetes Key Companies

14. PreDiabetes Key Products

15. PreDiabetes Unmet Needs

16 . PreDiabetes Market Drivers and Barriers

17. PreDiabetes Future Perspectives and Conclusion

18. PreDiabetes Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=prediabetes-pipeline-2024-key-developments-emerging-therapies-and-clinical-trials-detailed-analysis-by-delveinsight-nanoprecision-medical-caelus-health-inversago-pharma-inc-haisco-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.